| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 50mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
CAY10471 primarily targets the Prostaglandin D2 receptor CRTH2 (also known as DP2), a G protein-coupled receptor involved in allergic and inflammatory responses. It binds to the human DP2 receptor with high affinity, exhibiting a Ki value of 0.6 nM. The compound also shows some affinity for the DP1 receptor, but with significantly lower potency (Ki = 1200 nM), indicating strong selectivity for DP2 over DP1. Additionally, CAY10471 exhibits very low binding affinity for the TP receptor (Ki > 10,000 nM), further confirming its specificity. By antagonizing the CRTH2 receptor, CAY10471 blocks the downstream signaling pathways activated by prostaglandin D2, thereby modulating immune cell chemotaxis and cytokine production.
|
|---|---|
| ln Vitro |
In PC12 cells, 15dPGJ2-induced p38 MAP kinase phosphorylation is greatly reduced by CAY10471 (1 μM; 1-24 hours) [1].
In vitro studies have demonstrated that CAY10471 effectively inhibits CRTH2-mediated cellular responses. At a concentration of 1 μM, CAY10471 significantly decreases 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2)-induced phosphorylation of p38 MAP kinase in PC12 cells. This indicates that the compound can block the activation of key inflammatory signaling pathways downstream of the CRTH2 receptor. The inhibitory effect on p38 MAPK phosphorylation was observed at both 1-hour and 24-hour time points, suggesting sustained activity. In primary cultured rat hippocampal neurons, CAY10471 has been used as a DP2 antagonist to study the role of the PGD2-DP signaling pathway in neuronal injury caused by aluminum overload, demonstrating its utility in neuroinflammation research. |
| ln Vivo |
In chronic contact hypersensitivity (CHS) and IgE-CAI models, CAY10471 (oral therapy; 2 mg/kg; challenge day 22 or more than 10 consecutive days) showed decreased inflammation. While it greatly reduces inflammation in mice, it only partially blocks CRTH2 [2]. When compared to the vehicle, CAY10471 (oral treatment; 20 mg/kg; twice daily; beginning 3/4/5 days before to UUO) dramatically reduced cortical interstitial collagen deposition (8.40% vs. 14.85%). When compared to vehicle, oral treatment of UUO after three days likewise significantly reduced cortical interstitial collagen deposition (9.63% vs. 14.44%). On cortical interstitial collagen deposition, however, oral treatment beginning five days after UUO had no effect in comparison to vehicle (14.61% vs. 15.09%). UUO stands for unilateral ureteral obstruction [3].
In vivo, CAY10471 has shown significant anti-inflammatory and anti-fibrotic effects in animal models. Oral administration of CAY10471 at 2 mg/kg once daily significantly suppresses inflammation in both chronic contact hypersensitivity (CHS) and IgE-CAI models in mice. In a unilateral ureteral obstruction (UUO) mouse model of renal fibrosis, oral administration of CAY10471 at 20 mg/kg twice daily, beginning 3 or 4 days before UUO, significantly attenuates interstitial collagen deposition in the renal cortex (8.40% vs 14.85% in vehicle). However, when administration was delayed until 5 days after UUO, the compound had little effect on collagen deposition, suggesting that early intervention is critical for its anti-fibrotic activity. |
| Enzyme Assay |
The non-cellular in vitro binding assay for CAY10471 typically involves radioligand binding competition experiments using membrane preparations from cells expressing human recombinant DP1 or DP2 receptors. Membranes are incubated with a fixed concentration of a radiolabeled ligand (e.g., [³H]PGD2) and varying concentrations of CAY10471 in a binding buffer for a specified period at room temperature. Non-specific binding is determined in the presence of an excess of unlabeled ligand. After incubation, the reaction mixture is harvested by rapid filtration onto glass fiber filters, followed by extensive washing to remove unbound radioactivity. The bound radioactivity on the filters is then measured using a liquid scintillation counter. The Ki values are calculated from the competition binding curves using the Cheng-Prusoff equation.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: PC12 Cell Tested Concentrations: 1 μM Incubation Duration: 1 or 24 hrs (hours) Experimental Results: Blocks 15d-PGJ2-induced p38 MAP kinase activation. Cellular assays for CAY10471 typically use cell lines endogenously or heterologously expressing the CRTH2 receptor, such as PC12 cells or primary cultures. Cells are seeded in multi-well plates and serum-starved before treatment. CAY10471 is pre-incubated with the cells at varying concentrations (e.g., 1 μM) for a specified duration, typically 1-24 hours. The cells are then stimulated with a CRTH2 agonist like 15d-PGJ2. Downstream signaling is assessed by preparing cell lysates and performing Western blot analysis with antibodies against phosphorylated p38 MAPK and total p38 MAPK to determine the inhibition of kinase activation. Alternatively, cell viability and cytotoxicity can be measured using MTT and LDH release assays, respectively. |
| Animal Protocol |
Animal/Disease Models: balb/c (Bagg ALBino) mouse, DP−/− mice, CRTH2−/− mice[2]
Doses: 2 mg/kg Route of Administration: po (po (oral gavage)) one time/day; on the 22nd day or for more than 10 days Challenge Experimental Results: Dramatically inhibited CHS and IgE-CAI inflammatory respons. Animal/Disease Models: C57BL/6 mice [3] Doses: 20 mg/kg Route of Administration: po (po (oral gavage)) twice (two times) daily; start 3/4/5 days before UUO Experimental Results: Slows the progression of renal fibrosis in obstructed kidneys. In vivo animal studies with CAY10471 are commonly conducted in mouse models of inflammation and fibrosis. In the chronic contact hypersensitivity (CHS) model, Balb/c mice are sensitized and challenged with a hapten. CAY10471 is administered orally at a dose of 2 mg/kg once daily, with the challenge occurring on day 22. Ear swelling is measured to assess the inflammatory response. In the unilateral ureteral obstruction (UUO) model, mice undergo surgery to obstruct one ureter. CAY10471 is given orally at 20 mg/kg twice daily, starting 3-5 days before or after the surgery. After the study, kidney tissues are harvested, and interstitial collagen deposition is quantified using histochemical staining (e.g., Masson's trichrome) and image analysis. |
| ADME/Pharmacokinetics |
As a small molecule antagonist, CAY10471 is expected to have favorable oral bioavailability and pharmacokinetic properties suitable for in vivo studies. Its solubility in various solvents like DMSO, ethanol, and water suggests it can be formulated for both in vitro and in vivo administration. For in vivo use, CAY10471 is typically formulated in vehicles such as 10% DMSO, 40% PEG300, 5% Tween-80, and 45% saline or similar aqueous solutions to ensure adequate systemic exposure following oral administration. No detailed pharmacokinetic parameters (such as half-life, Cmax, or AUC) have been reported in the available literature for CAY10471.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for CAY10471 have not been extensively reported in the available literature. However, based on its use in animal models at doses such as 20 mg/kg orally twice daily, the compound appears to be tolerated in mice with no overt signs of toxicity reported. As a research chemical, CAY10471 is not intended for human therapeutic use and is strictly for preclinical research purposes. Standard safety precautions should be taken when handling this compound, including the use of personal protective equipment and working in a well-ventilated fume hood, as is typical for chemical research reagents.
|
| References |
|
| Additional Infomation |
Prostaglandin D2 receptor antagonists; structure described in the first article.
CAY10471, also known as TM30089, is a chemical tool for studying the role of the CRTH2/DP2 receptor in various pathophysiological conditions. It is more potent and selective than its parent compound Ramatroban (BAY-u3405). The compound has been instrumental in demonstrating the involvement of the PGD2-CRTH2 axis in inflammation and fibrosis. While it is a valuable research tool, CAY10471 has not been approved for clinical use and is not in clinical trials. Its primary application is in academic and pharmaceutical research to validate CRTH2 as a therapeutic target for diseases such as asthma, allergic rhinitis, and fibrotic disorders. |
| Molecular Formula |
C21H21FN2O4S
|
|---|---|
| Molecular Weight |
416.46600
|
| Exact Mass |
416.12
|
| CAS # |
627865-18-3
|
| Related CAS # |
CAY10471 Racemate;844639-57-2
|
| PubChem CID |
11384493
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
654.7±65.0 °C at 760 mmHg
|
| Flash Point |
349.7±34.3 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.664
|
| LogP |
4.09
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
704
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C1CCC2=C(C1)C3=CC=CC=C3N2CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F
|
| InChi Key |
CANCTKXGRVNXFP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-15)17-4-2-3-5-19(17)24(20)13-21(25)26/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)
|
| Chemical Name |
(+)-3-[[(4-fluorophenyl)sulfonyl]methylamino]-1,2,3,4-tetrahydro-9H-carbazole-9-acetic acid
|
| Synonyms |
CAY-10471 CAY 10471 CAY10471 TM30089 TM-30089 TM 30089
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4011 mL | 12.0057 mL | 24.0113 mL | |
| 5 mM | 0.4802 mL | 2.4011 mL | 4.8023 mL | |
| 10 mM | 0.2401 mL | 1.2006 mL | 2.4011 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
